Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease-Reference-Cited by-同舟云学术

Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease

Published:2016 Issue:6 Volume:23 Page:746-756
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Yamashita Shizuya¹²,Masuda Daisaku³,Ohama Tohru³⁴,Arai Hidenori⁵,Bujo Hideaki⁶,Kagimura Tatsuo⁷,Kita Toru⁸,Matsuzaki Masunori⁹,Saito Yasushi¹⁰,Fukushima Masanori⁷,Matsuzawa Yuji¹¹,

Affiliation:

1. Department of Community Medicine, Osaka University Graduate School of Medicine

2. Rinku General Medical Center

3. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

4. Department of Dental Anesthesiology, Osaka University Graduate School of Dentistry

5. The National Center for Geriatrics and Gerontology

6. Department of Clinical Laboratory and Experimental Research Medicine, Toho University, Sakura Medical Center

7. Foundation for Biomedical Research and Innovation

8. Kobe City Medical Center General Hospital

9. Yamaguchi University Graduate School of Medicine

10. Chiba University Graduate School of Medicine

11. Sumitomo Hospital

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/23/6/23_32813/_pdf

Reference62 articles.

1. 1) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb. 2013; 20: 517-523

2. 2) Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian SimvastatinSurvival Study (4S). The Lancet. 1994; 344: 1383-1389

3. 3) Plehn J F, Davis B R, Sacks F M, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E: Reduction of Stroke Incidence After Myocardinal Infarction With Pravastatin The cholesterol and recurrent events (CARE) study Circulation. 1999; 99: 216-223

4. 4) The Long-Term Intervention with Pravastatin in Ischaemic Disiese (LIPID) Study Group: Prevention of Cardiovascular events and death with Pravastatin in patient with Coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349-1357

5. 5) Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-445

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Probucol mitigates high-fat diet-induced cognitive and social impairments by regulating brain redox and insulin resistance;Frontiers in Neuroscience;2024-04-23

2. The pathophysiology of excess plasma-free cholesterol;Current Opinion in Lipidology;2023-09-25

3. Probucol mitigates high-fat diet-induced cognitive and social impairments through disruption of redox-inflammation association;2023-09-05

4. Density functional studies of probucol excited states and spectral properties;The European Physical Journal D;2023-01

5. Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study;Journal of Atherosclerosis and Thrombosis;2021-02-01